Skip to the lineages
Regenerative Medicine

What Should Be Included in Informed Consent for an Experimental Biologic Injection?

Published November 16, 2026

Protocol: 9 steps in this guide
  1. What counts as investigational
  2. Expected and unknown benefit
  3. Known risks, unknown risks and product source
  4. Other options and standard treatment
  5. Costs and injury compensation
  6. Privacy, data and contacts
  7. Withdrawal and follow-up
  8. Reader's checklist
  9. Clinical consent versus research consent

If the injection is given as part of FDA-regulated research, federal rules list what you must be told: that the study involves research and which procedures are experimental, the reasonably foreseeable risks, the benefits that may reasonably be expected, appropriate alternatives, how your records will be kept confidential, what happens if you are injured, whom to contact, and that taking part is voluntary. Those rules are in 21 CFR 50.25, available in the Legal Information Institute’s copy of 21 CFR 50.25. A signed form does not make an unapproved treatment effective, legal or advisable; it records what you were told.

What counts as investigational

The first required element is a statement “that the study involves research, an explanation of the purposes of the research and the expected duration of the subject’s participation, a description of the procedures to be followed, and identification of any procedures which are experimental.” Before you sign, you should be able to say in your own words what is being tested, why, for how long, and which parts of your care are experimental. Ask for the exact product name, who makes it, and whether the study runs under an Investigational New Drug application (IND); what an IND means is covered in what it means when an FDA investigational new drug application is in effect.

Expected and unknown benefit

The rule requires a description “of any benefits to the subject or to others which may reasonably be expected from the research.” The phrase “may reasonably be expected” matters. If the treatment is being studied, its benefit has not yet been shown, and a consent form should not read like an advertisement. Benefit to others, such as knowledge gained for future patients, can be a real benefit of research even when there is none for you.

Known risks, unknown risks and product source

The rule requires a description “of any reasonably foreseeable risks or discomforts to the subject.” When appropriate, it also requires a statement that the treatment “may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable.” For cell and tissue products, ask where the material comes from (your own body or a donor), how it is processed and how it is tested. FDA’s patient and consumer information on regenerative medicine therapies lists safety concerns with illegally marketed products, including bacterial infections, unwanted inflammatory or immune responses, tumor formation, and contamination “related to processing (preparation of the product) or the therapy not being tested for infectious diseases such as hepatitis and HIV.” Product-specific risks are covered in the potential risks of A2M joint injections and the risks of immune reactions to donor-derived cell products.

Other options and standard treatment

The rule requires a disclosure “of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject.” A consent discussion that presents the experimental injection as the only option leaves out a required element. Ask which established treatments exist for your condition and what would happen if you chose none of them.

Costs and injury compensation

When appropriate, the rule requires disclosure of any additional costs “to the subject that may result from participation in the research.” For research involving more than minimal risk, it requires an explanation of whether any compensation and any medical treatments are available if injury occurs, and, if so, what they consist of or where to find out more. Get both answers in writing: what you will pay, and who pays if something goes wrong. Questions about pricing are covered in why stem cell injection prices vary so widely.

Privacy, data and contacts

The rule requires a statement about the extent to which confidentiality of records identifying you will be kept, noting “the possibility that the Food and Drug Administration may inspect the records.” It also requires an explanation “of whom to contact for answers to pertinent questions about the research and research subjects’ rights, and whom to contact in the event of a research-related injury to the subject.” For applicable clinical trials, the form must include a statement that a description of the trial will be available on ClinicalTrials.gov; what such a listing does and does not mean is covered in whether listing a study on ClinicalTrials.gov means a treatment is approved.

Withdrawal and follow-up

The rule requires a statement that “participation is voluntary,” that refusing involves no penalty or loss of benefits you are otherwise entitled to, and that you may stop at any time without penalty. When appropriate, the form also explains the consequences of withdrawing and how to stop in an orderly way, the circumstances in which the investigator may end your participation, that significant new findings will be shared with you, and the approximate number of people in the study. A companion section, 21 CFR 50.20, requires that consent be sought with “sufficient opportunity to consider whether or not to participate,” in “language understandable to the subject,” and without language through which you waive or appear to waive any of your legal rights.

Reader’s checklist

This checklist is ours, organized around the elements above. Bring it to the consent discussion.

Topic Question to ask Answer received
Research status What is being tested, and which parts are experimental?
Product What is the exact product, its source and its maker?
Oversight Is there an IND, and who is the sponsor?
Benefit What benefit, if any, can reasonably be expected?
Risks What risks are known, and what is still unknown?
Alternatives What established treatments could I choose instead?
Costs What will I pay, and for what?
Injury What happens, and who pays, if I am harmed?
Privacy Who can see my records?
Contacts Whom do I call with questions or after an injury?
Withdrawal How do I stop, and what follow-up is needed?

Clinical consent versus research consent

These rules apply to research covered by FDA’s regulations. Section 50.20 refers to “research covered by these regulations,” and 50.25(d) states that the requirements do not preempt other federal, state or local laws that require additional information. A clinic offering an injection as a routine paid service is not running a study just because it gives you a consent form, and a clinic that calls a paid service a “study” should be able to show the IND, the sponsor and the research protocol. FDA’s patient notice states that the unapproved regenerative products it warns about “have not been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain,” and that such products “require FDA oversight in a clinical trial” before approval.

Informed consent for an experimental biologic injection in FDA-regulated research must explain the research, the experimental procedures, foreseeable and unknown risks, expected benefits, alternatives, costs, injury care, privacy, contacts and your right to stop, but a complete consent form describes the risks of an unproven treatment; it does not make that treatment proven, approved or right for you.

Cells linked to this one

This guide leads on to

Guides that lead here

Lineage I: Patient Safety, Scientific Literacy and FDA Verification

What readers added

Add a remark

Your email address will not be published. Required fields are marked *